Piper Jaffray & Co. initiates coverage on Genzyme (Nasdaq: GENZ) with a Buy ratinga�and $86 price target, citing steady growth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE